CalciMedica (CALC) Stock Price, News & Analysis

Company Overview

CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research is centered on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead investigational product is Auxora, also known as zelnecirnon or CM4620. The selective CRAC channel inhibitor has been evaluated in clinical studies for conditions including acute pancreatitis and associated acute kidney injury, as well as other diseases involving excessive inflammation. Auxora remains an investigational therapy and has not been approved for commercial use.

CalciMedica was founded in 2007 and is based in La Jolla, California. The company became publicly traded on the Nasdaq under the symbol CALC following a business combination with Graybug Vision that was completed in 2023. Its clinical development activities have primarily involved studies in the United States, with potential applications for its platform being evaluated across multiple inflammatory disease areas.

Key Stats

• Today's Range: $1.58 to $1.70
• 50-Day Range: $1.60 to $5.00
• 52-Week Range: $1.58 to $36.00
• Volume: 21,711 shs
• Average Volume: 67,026 shs
• Market Capitalization: $10.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Hold

CalciMedica Stock Analysis - MarketRank™

CalciMedica scored higher than 60% of companies evaluated by MarketBeat, and ranked 334th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

CalciMedica has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

CalciMedica has a consensus price target of $50.00, representing about 3,025.0% upside from its current price of $1.60.

Amount of Analyst Coverage

CalciMedica has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CalciMedica are expected to grow in the coming year, from ($5.25) to ($3.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CalciMedica is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CalciMedica is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.28% of the float of CalciMedica has been sold short.

Short Interest Ratio / Days to Cover

CalciMedica has a short interest ratio ("days to cover") of 1.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CalciMedica has recently decreased by 12.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CalciMedica does not currently pay a dividend.

Dividend Growth

CalciMedica does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for CALC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CalciMedica insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.25% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

CalciMedica has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CALC
• CIK: 1534133
• Web: www.calcimedica.com
• Phone: 858-952-5500
• Fax: N/A
• Employees: 15
• Year Founded: 2007

Price Target and Rating

• Average Price Target for CalciMedica: $50.00
• High Price Target: $50.00
• Low Price Target: $50.00
• Potential Upside/Downside: +3,025.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -155.24%

Debt

• Debt-to-Equity Ratio: 1.67
• Current Ratio: 5.58
• Quick Ratio: 5.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.30) per share
• Price / Book: -0.70

Miscellaneous

• Outstanding Shares: 6,830,000
• Free Float: 4,899,000
• Market Cap: $10.93 million
• Optionable: No Data
• Beta: 0.76